应重视化疗在肌层浸润性膀胱癌保留膀胱治疗中的作用

doi:10.3969/j.issn.1006-7795.2014.03.001

摘要/Abstract

摘要：

化疗是近年来肌层浸润性膀胱癌重要的辅助治疗手段，对于临床要求保留膀胱的患者意义重大。本文介绍了新辅助化疗和辅助化疗的作用及效果，对经尿道根治性膀胱肿瘤切除术（transurethral resection of bladder tumor，TURBT）联合化疗以及膀胱部分切除术联合化疗的方法及疗效进行综述，同时对一些特殊患者例如肾脏移植患者及透析患者的化疗进行了介绍；最后对当前化疗中存在的药物敏感性问题加以阐述，并对今后化疗在肌层浸润性膀胱癌保留膀胱的发展前景进行了展望。

关键词: 化疗, 膀胱癌, 经尿道膀胱肿瘤切除, 膀胱部分切除

Abstract:

Chemotherapy has been developing to be an important adjuvant treatment methods in treatment of muscle invasive bladder cancer in recent years. Such method is meaningful for patients who want to preserve the bladder. The author summarized the role and effect of neoadjuvant chemotherapy and adjuvant chemotherapy. This article reviews the methods and effect of radical transurethral resection of bladder tumor with chemotherapy and partial cystectomy with chemotherapy. Data of several special patients including patients with renal transplantation and dialysis patients undergoing chemotherapy are presented. The problems existing in current drug sensitivity of chemotherapy are discussed finally. The future of chemotherapy in muscle invasive bladder cancer with bladder preservation is predicted.

Key words: chemotherapy, muscle invasive bladder cancer, transurethral resection of bladder tumor, partial cystectomy

中图分类号:

R737.14

田野. 应重视化疗在肌层浸润性膀胱癌保留膀胱治疗中的作用[J]. 首都医科大学学报, 2014, 35(3): 269-272.

Tian Ye. Applications of chemotherapy in muscle invasive bladder cancer with bladder preservation[J]. Journal of Capital Medical University, 2014, 35(3): 269-272.

参考文献

[1] Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012[J]. CA Cancer J Clin, 2012, 62(5):283-298.
[2] Martini T, Mayr R, Wehrberger C, et al. Comparison of radical cystectomy with conservative treatment in geriatric(≥80) patients with muscle-invasive bladder cancer[J]. Int Braz J Urol, 2013, 39(5):622-630.
[3] Kitagawa Y, Izumi K, Miwa S, et al. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer[J]. Anticancer Res, 2013, 33(10):4497-4503.
[4] 樊晓栋, 姜庆, 王家武.新辅助化疗对肌层浸润性膀胱癌预后影响的Meta分析[J].第三军医大学学报, 2011, 33(2):196-199.
[5] Teramukai S, Nishiyama H, Matsui Y, et al. Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer[J]. Clin Cancer Res, 2006, 12(1):139-143.
[6] Bellmunt J, von der Maase H, Mead G M, et al. Randomized phase Ⅲ study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987[J]. J Clin Oncol, 2012, 30(10):1107-1113.
[7] Volkmer B G, Kuefer R, Bartsch G Jr, et al. Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival[J]. Cancer, 2005, 104(11):2384-2391.
[8] 李双辉, 张志宏, 徐勇, 等.根治性经尿道膀胱肿瘤电切术加化疗治疗肌层浸润性膀胱癌的疗效分析[J].中华泌尿外科杂志, 2012, 33(3):215-218.
[9] Balar A, Bajorin D F, Milowsky M I. Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy[J]. Ther Adv Urol, 2011, 3(3):107-117.
[10] Mayadagli A, Kocak M, Demir O, et al. Elective bladder preservation with multimodality treatment for bladder cancer[J]. J BUON, 2012, 17(3):483-489.
[11] Tunio M A, Hashmi A, Rafi M, et al. Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation(SIUT)[J]. J Pak Med Assoc, 2011, 61(1):6-10.
[12] Hsu C Y, McCulloch C E, Iribarren C, et al. Body mass index and risk for end-stage renal disease[J]. Ann Intern Med, 2006, 144(1):21-28.
[13] Smith Z L, Christodouleas J P, Keefe S M, et al. Bladder preservation in the treatment of muscle-invasive bladder cancer(MIBC): a review of the literature and a practical approach to therapy[J]. BJU Int, 2013, 112(1):13-25.
[14] Biagioli M C, Fernandez D C, Spiess P E, et al. Primary bladder preservation treatment for urothelial bladder cancer[J]. Cancer Control, 2013, 20(3):188-199.
[15] Koga F, Kihara K, Yoshida S, et al. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients[J]. BJU Int, 2012, 109(6):860-866.
[16] Kassouf W, Swanson D, Kamat A M, et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience[J]. J Urol, 2006, 175(6):2058-2062.
[17] 王平, 沈思瑶, 薄隽杰, 等.膀胱部分切除术联合化疗治疗肌层浸润性膀胱癌的临床疗效分析[J].中国癌症杂志, 2012, 22(10):766-769.
[18] 马宝杰, 李海波, 张昌文, 等.膀胱部分切除术治疗盆腔淋巴结阴性的肌层浸润性膀胱癌100例生存分析[J].中华泌尿外科杂志, 2013, 34(5):347-351.
[19] 田野.应重视肌层浸润性膀胱癌的化疗策略[J].中华医学杂志, 2012, 92(6):363-365.
[20] Foote M. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel[J]. Biotechnol Annu Rev, 2007, 13:345-357.
[21] Hussain M H, MacVicar G R, Petrylak D P, et al. Trastazumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase Ⅱ national cancer institute trial[J]. J Clin Oncol, 2007, 25(16):2218-2224.
[22] Wulfing C, Machiels J P, Richel D J, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma[J].Cancer, 2009, 115(13):2881-2890.
[23] Gallagher D J, Milowsky M I, Gerst S R, et al. Phase Ⅱ study of sunitinib in patients with metastatic urothelial cancer[J]. J Clin Oncol, 2010, 28(8):1373-1379.
[24] Philips G K, Halabi S, Sanford B L, et al. A phase Ⅱ trial of cisplatin(C), gemcitabine(G) and gefitinib for advanced urothelial tract carcinoma: results of cancer and 1eukemia group B(CALGB)90102[J]. Ann Oncol, 2009, 20(6):1074-1079.